Onesource Specialty Pharma Limited — Important, 04-08-2025: Updates

OneSource Specialty Pharma's Board has given in-principle approval to evaluate acquiring Sterile Injectable CDMO and CMO businesses from Steriscience SG and Brooks Steriscience. This strategic move could bring a USFDA-approved sterile fill-finish facility in Poland and a USFDA-approved carbapenem facility in India into OneSource. The potential acquisition, from promoter-owned entities, expands CDMO/CMO capabilities significantly, enhancing global reach and serving key partners. Management is authorized to conduct detailed evaluations and appoint necessary consultants.